Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk

Pfizer

Medicare's decades-old exclusion of weight-loss drug coverage is coming under scrutiny amid mounting evidence that Wegovy and similar medications have health benefits that extend well beyond shedding pounds.

Medicare's exclusion of weight-loss drug coverage under fire

Apple

Fidelity MSCI Information Technology Index ETF

iShares U.S. Technology ETF

Roundhill Magnificent Seven ETF

Microsoft

NVIDIA

VanEck Vectors Semiconductor ETF

Vanguard Consumer Discretionary ETF

Vanguard Telecommunication Services ETF

Communication Services Select Sector SPDR Fund

Technology Select Sector SPDR Fund

The latest 13-F filings of billionaires indicate that most are still bullish on big techs.

Billionaires Bullish on Big Tech: ETFs in Focus

Weight loss was the talk of this earnings season, making names such as Wegovy, Ozempic and Mounjaro the water-cooler discussion that companies across the globe could not ignore.

Wegovy craze was all the rage on Q3 earnings calls

Eli Lilly's approval for its obesity drug Zepbound is a huge step forward in its attempt to take market share from its top rival Novo Nordisk. The combination of Mounjaro and Zepbound could reach nearly $70 billion of annual revenue.

Eli Lilly Just Got One Step Closer to Dethroning Ozempic. Time to Buy the Stock?

Popular weight loss drugs Wegovy and Zepbound will soon be available in pill form. Pharmaceutical giants Novo Nordisk (NYSE:NVO) and Eli Lilly and Co (NYSE:LLY) are actively promoting pill versions of their successful weight-loss drugs, expected to hit the market as early as next year, Bloomberg reported.

Weight loss drugs Wegovy and Zepbound to debut in pill form

Eli Lilly and Co (NYSE:LLY) has announced plans for a new $2.5 billion high-tech manufacturing site in Germany to expand its global parenteral (injectable) product and device manufacturing network. The company said the site in Alzey, Rhineland-Palatinate, its sixth in Europe, will also support an increased demand for Lilly's medicines, including its diabetes and obesity portfolio.

Eli Lilly plans $2.5B site in Germany to expand injectable manufacturing capacity

Amazon

Alibaba

Bank of America

Coupang

General Motors

Johnson & Johnson

Procter & Gamble

Teck Resources

Stock Strategist Andrew Rocco divulges valuable insights from the world's best and brightest investors.

13F Rundown: Tepper, Buffett, Druckenmiller

Eli Lilly will build its first plant in Germany for 2.3 billion euros ($2.5 billion) in the western town of Alzey, the U.S. pharmaceuticals maker said on Friday, as the sector scrambles to meet demand for new diabetes and obesity therapies.

Lilly to build $2.5 bln diabetes drug plant in Germany

Shares of Eli Lilly & Co. LLY, +0.04% rose 0.67% in premarket trading Friday after drug giant announced plans to spend $2.5 billion to build a new manufacturing facility in Germany. The new facility is aimed at expanding Lilly's injectable product and device manufacturing capacity, to support the increased demand seen for company's obesity and diabetes drugs.

Eli Lilly to build $2.5 billion plant in Germany to support rising demand for obesity, diabetes drugs

Retail flows into Eli Lilly spiked to a more than two-year high in November, as small investors rushed to buy the stock after the U.S. pharma major received a highly anticipated approval for its weight-loss drug Zepbound. Daily net purchases surged to $14.4 million on Nov. 8, when Zepbound was cleared in the U.S. and the U.K., hitting their highest levels since January 2021, as per data from Vanda Research.

Retail investors crowd into Eli Lilly after weight-loss drug approval

Company also commits to investing up to $100 million in German early-stage life sciences ecosystem INDIANAPOLIS , Nov. 17, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced plans to construct a new $2.5 billion high-tech manufacturing site in Alzey, Rhineland-Palatinate, Germany. This new facility will further expand the company's global parenteral (injectable) product and device manufacturing network and support an increased demand for Lilly's medicines, including its diabetes and obesity portfolio.

Lilly to expand injectable manufacturing capacity with planned $2.5 billion site in Germany

Point Biopharma Global

Eli Lilly on Friday extended the deadline for Point Biopharma Global shareholders by about two weeks to Dec. 1 to sell their stock, due to low participation.

Eli Lilly extends tender offer to buy Point Biopharma after low participation

INDIANAPOLIS , Nov. 17, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ: PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. The tender offer, which was previously scheduled to expire at 5:00 p.m.

Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023

Is Eli Lilly stock a buy after the FDA approved its new weight-loss drug, Zepbound? Is LLY stock a buy right now?

Is Eli Lilly Stock A Buy After The FDA Signs Off On Its New Weight-Loss Drug?

Novo Nordisk and Eli Lilly are both leaders in the diabetes care market. Both have been recording excellent financial results for most of the year.

Better Growth Stock: Novo Nordisk vs. Eli Lilly

This iron condor trade on Lilly stock has the potential to return 27% if the stock price stays between about 510 and 680.

This Option Trade On Eli Lilly Stock Could Return 27% By Mid-January

U.S. pharmaceuticals company Eli Lilly plans to build a new plant in western Germany, sources close to the matter told Reuters, with one putting the investment at 2 bln euros

Eli Lilly plans new 2 billion euro German plant -source

Eli Lily has the highest market capitalization of any Healthcare company, but its low revenue does not justify its lofty valuation at first glance. However, the company's average 5-year forward growth of 16.8% explains the market's pricing of its stock. With a steady pipeline of products with a high focus on Diabetes/Obesity drugs, the company's outlook certainly justifies its position as the highest-valued healthcare stock.

Eli Lilly: Perfectly Priced Healthcare Giant

U.S. pharma company Eli Lilly plans to invest 2 billion euros ($2.17 billion) in a new plant in Alzey, western Germany, a source close to the negotiations told Reuters on Thursday.

Eli Lilly plans to invest 2 bln euros in new German plant -source

Bristol-Myers

VanEck Vectors Pharmaceutical ETF

Despite Eli Lilly's monster 66.8% gain on the year because of weight-loss drugs, the S&P 500 Pharmaceuticals index is down 2.3%.

Pharma Is Out of Favor. 5 Drug Stocks With Room to Grow.

A media report stated that the pharmaceutical giant intends to build a new factory in Germany. It will apparently fund the project entirely on its own.

Why Eli Lilly Stock Flopped While the Market Popped Today

U.S. pharma giant Eli Lilly plans an investment in the single-digit billion dollar range in a new plant in western Germany, people familiar with the matter told Reuters after the company called a press conference for Friday.

Lilly plans single-digit billion dollar new German plant - sources

Some big investors showed increased appetite for weight-loss drug makers in the third quarter, piling in to shares of Eli Lilly and Novo Nordisk amid growing demand for their product, securities filings showed on Tuesday.

Investors increase holdings of weight-loss drug makers' shares in Q3 -filings

INDIANAPOLIS , Nov. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Nuclear Regulatory Commission ("NRC") has issued its consent for the indirect transfer of control of POINT Biopharma Global Inc.'s (NASDAQ: PNT) radioactive materials license (the "NRC Consent"), which will occur following the completion of Lilly's previously announced tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT, for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. Obtaining the NRC Consent is the last regulatory approval necessary for the consummation of the transaction.

Lilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT Biopharma

Riot Blockchain

Tesla

Stock gains are great, but they don't necessarily continue forever. Today's fast rising investment can be tomorrow's disappointment.

News for Eli Lilly Stock (LLY)